Diversity in the lysis-integration region of oenophage genomes and evidence for multiple tRNA loci, as targets for prophage integration in Oenococcus oeni

Virology
Carlos São-JoséMário A Santos

Abstract

The central genomic regions of Oenococcus oeni phages fOg30 and fOgPSU1 have been compared with the equivalent regions of oenophages fOg44 and phi 10MC. In all cases, an almost identical endolysin gene was followed by one of two orfs, encoding putative holins (orf117 and orf163). The fOg44 endolysin was established as a secretory protein when expressed in Lactococcus lactis. Orf117 (from fOg44) promoted lysis of Escherichia coli cultures upon induction of a defective lambda Sam7 prophage, but Orf163 (from fOg30) failed to elicit a lysis response in this system. fOg44 and fOgPSU1 were shown to integrate at the 3' end of a tRNA(Glu) and a tRNA(Lys), respectively. Searching the available sequence of the O. oeni MCW genome for attP-like elements, two other tRNA targets could be proposed for prophage establishment. Between the lysis and integration elements, a diverse cluster of genes (absent in phi 10MC) was observed. One common gene in this "lysogenic conversion cluster" was experimentally confirmed as a transcriptional repressor, affecting the expression of a putative permease gene.

References

Sep 1, 1991·Journal of General Microbiology·E K ArendtW P Hammes
Apr 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·C T ChungR H Miller
May 15, 1998·Archives of Virology·R SantosM A Santos
Jul 27, 1999·Molecular Microbiology·A Graschopf, U Bläsi
Mar 9, 2000·Trends in Microbiology·I YoungW D Roof
Mar 14, 2000·FEMS Microbiology Letters·N VukovM J Loessner
Oct 6, 2000·Annual Review of Microbiology·I N WangR Young
Mar 22, 2001·Proceedings of the National Academy of Sciences of the United States of America·D NelsonV A Fischetti
Sep 5, 2001·Molecular Microbiology·E Ramanculov, R Young
Sep 7, 2001·Annual Review of Microbiology·H Brussow
Aug 23, 2002·Nature·Raymond SchuchVincent A Fischetti
Jul 18, 2003·Journal of Bacteriology·Marco VenturaHarald Brüssow
Aug 28, 2003·Current Opinion in Microbiology·Carlos CanchayaHarald Brüssow
Oct 24, 2003·Current Opinion in Microbiology·Roger W Hendrix

❮ Previous
Next ❯

Citations

Nov 6, 2007·Journal of Bacteriology·João Gil NascimentoMário Almeida Santos
Feb 17, 2009·Applied and Environmental Microbiology·Elisabeth BonClaire Le Marrec
Oct 9, 2015·Scientific Reports·Marc MonotBruno Dupuy
Oct 10, 2012·FEMS Microbiology Reviews·Maria João CatalãoMadalena Pimentel
Sep 3, 2013·International Journal of Food Microbiology·Fety JaomanjakaClaire Le Marrec
Mar 26, 2013·Applied and Environmental Microbiology·Zohra JamalMarguerite Dols-Lafargue
Jun 28, 2018·Frontiers in Microbiology·Maria DimopoulouMarguerite Dols-Lafargue
May 1, 2021·Microorganisms·Olivier ClaisseClaire Le Marrec

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthrax

Anthrax toxin, comprising protective antigen, lethal factor, and oedema factor, is the major virulence factor of Bacillus anthracis, an agent that causes high mortality in humans and animals. Here is the latest research on Anthrax.

Anthrax Vaccines

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.

Bacteriophage: Phage Therapy

Phage therapy uses bacterial viruses (bacteriophages) to treat bacterial infections and is widely being recognized as an alternative to antibiotics. Here is the latest research.

Anthrax Vaccines (ASM)

Three different types of anthrax vaccines are available; a live-attenuated, an alum-precipitated cell-free filtrate and a protein recombinant vaccine. The effectiveness between the three is uncertain, but the live-attenuated have shown to reduce the risk of anthrax with low adverse events. Here is the latest research on anthrax vaccines.